Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03824275 · ClinicalTrials.gov registry record · Phase 2
18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer
A Phase 2 study of Prostatic Neoplasms, sponsored by Columbia University.
- Active
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
- 1
- Study location
NCT03824275 is a Phase 2 study of Prostatic Neoplasms that is active but no longer recruiting, run by Columbia University. The registered enrollment target is 129 participants, below the 512-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03824275, a Phase 2 study of Prostatic Neoplasms, is active but no longer recruiting, sponsored by Columbia University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
- 1
- Study location
Study Summary
PyL, also known as \[18F\]DCFPyL, is a second-generation fluorinated prostate-specific membrane antigen (PSMA) targeted PET imaging agent. In preliminary studies it demonstrates a higher detection of metastatic prostate lesions compared to standard imaging. Its ability to image metastatic prostate cancer sites was comparable to 68Ga-PSMA with high tumor-to-background ratios.Additionally, \[18F\] PyL demonstrated higher mean tumor-to-background ratios when using kidney, spleen, or parotid as reference organs. However, the role of \[18F\] PyL in tumor response to therapy has not been evaluated, specifically the potential to serve as a predictive biomarker of response. Given the high cost of current therapeutic agents in mCRPC, there is a need for an early response biomarker to stratify which patients will benefit from therapy and which will not. This will also allow for earlier change in management of patients who will not response to these therapies, potentially improving patient outcomes.
Conditions Studied
Interventions
- DRUG 18F- DCFPyL PET/CT
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2019-02-12 |
| Est. Completion | 2023-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03824275
The ClinicalTrials.gov registry entry for NCT03824275 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 512-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (75% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which 18F- DCFPyL PET/CT is the first listed.
NCT03824275 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03824275 about?
NCT03824275 is a clinical study titled "18F-DCFPyL Positron Emission Tomography (PET)/Computed Tomography (CT) in Men With Prostate Cancer". PyL, also known as \[18F\]DCFPyL, is a second-generation fluorinated prostate-specific membrane antigen (PSMA) targeted PET imaging agent. In preliminary studies it demonstrates a higher detection of metastatic prostate lesions compared to standard imaging. Its ability to image metastatic prostate c...
What is the current status of trial NCT03824275?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2019-02-12. Estimated completion is 2023-12.
What conditions does trial NCT03824275 study?
This clinical trial studies the following conditions: Prostatic Neoplasms.
What interventions are being tested in trial NCT03824275?
The interventions under investigation include: 18F- DCFPyL PET/CT (DRUG).
Who is sponsoring clinical trial NCT03824275?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03824275 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostatic Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
RECRUITING · Phase 2
-
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
RECRUITING · Phase 2
-
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
RECRUITING · Phase 2
-
A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts
ACTIVE NOT RECRUITING · Phase 2
-
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Randomized Phase IIa Efficacy and Safety Study of Radium-223 Dichloride With Abiraterone Acetate or Enzalutamide in Metastatic Castration-resistant Prostate Cancer (CRPC)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.